7 min read · May 2026
BELIEVE Trial Results: The Muscle-Preserving GLP-1 Combination
Trial highlight: The BELIEVE trial (Nature Medicine, March 2026) showed that combining semaglutide with bimagrumab produced 22.1% weight loss — with 92.8% of that weight coming from fat and only 7.2% from lean muscle mass.
The single biggest criticism of GLP-1 medications is muscle loss. Roughly 25-40% of weight lost on semaglutide alone comes from lean tissue — not fat. The BELIEVE trial may have found the answer.
The Study Design
BELIEVE was a Phase 2b randomized controlled trial testing bimagrumab (an anti-myostatin antibody that blocks muscle breakdown) combined with semaglutide 2.4mg in adults with obesity. Published in Nature Medicine in March 2026, it's the most significant body composition study in the GLP-1 era.
The Results
| Outcome | Semaglutide Alone | Semaglutide + Bimagrumab |
|---|---|---|
| Total weight loss | ~15-17% | 22.1% |
| Fat mass loss (% of total loss) | ~60-75% | 92.8% |
| Lean mass loss (% of total loss) | ~25-40% | 7.2% |
The numbers are striking. The combination didn't just preserve muscle — it concentrated weight loss almost entirely in fat tissue. At 92.8% fat mass loss, the body composition outcome approaches what you'd see from a highly disciplined resistance training + caloric deficit program, but with far greater total weight loss.
What This Means for Compounded GLP-1 Users
Bimagrumab is not yet available as a combination product — Phase 3 trials are ongoing and FDA approval is likely 2-3 years away. But the BELIEVE trial validates two principles that patients can act on today.
First, muscle loss on GLP-1s is a real problem worth addressing. This isn't fear-mongering — it's confirmed by rigorous clinical data. If a pharmaceutical company is investing hundreds of millions to develop a muscle-preservation add-on, the problem is clinically significant.
Second, the muscle can be preserved. While bimagrumab uses a pharmacological approach, the lifestyle equivalent — resistance training + adequate protein (1.5g/kg fat-free mass, per Spreckley IJO 2026) — is the best available strategy today.
Practical Takeaways
Resistance train 2-3 times per week, prioritizing compound movements (squats, deadlifts, rows, presses). Target 1.5g protein per kg of fat-free mass daily. Track body composition, not just scale weight — a DEXA scan every 3-6 months provides the most accurate picture.
If your provider isn't discussing muscle preservation as part of your GLP-1 protocol, consider one who does.
Embody
Injectable semaglutide with physician-guided dosing protocols.
Compounded medications are not FDA-approved.
Learn More Paid linkCare Bare Rx
Licensed physicians with ongoing monitoring and dose adjustments.
Compounded medications are not FDA-approved.
Learn More Paid linkCompare GLP-1 Providers Side by Side
See pricing, medications, and ratings for verified telehealth providers.
View Provider Comparison →Sources
- Heymsfield SB, et al. "Bimagrumab and Semaglutide for Obesity." Nature Medicine, March 2026.
- Spreckley M, et al. "Protein Intake on GLP-1 RAs." Int J Obesity, 2026.
- Phillips SM. "Protein Requirements During Weight Loss." Am J Clin Nutr, 2024.
Medical Disclaimer: This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
FDA Notice: Compounded medications referenced in this article are not FDA-approved. Only brand-name GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) carry FDA approval for their indicated uses.